The pharmaceutical giant is now considered one of Morningstar's highest-conviction undervalued stocks, citing a robust pipeline and strategic acquisitions.
Shares fall despite strong Q3 sales, as expiring EV tax credits and valuation concerns spook investors.
The utility giant reaffirmed its adjusted EPS targets for 2025 and 2026, reinforcing a long-term earnings growth strategy of 7% to 9% through 2029.
A coalition of influential investors is urging shareholders to reject the CEO's new compensation package, citing major governance concerns.
H.C. Wainwright more than doubles its price target to $7 as the company delivers its first electrolyzer to a major green hydrogen facility in Portugal.
Analyst sets a new $70 price target, citing strong revenue forecasts and potential for margin expansion for the airline carrier.
Analyst cites a 'stronger for longer' demand cycle for hard disk drives, fueled by the explosive growth of cloud computing and AI.
Analysts cite strong fundraising and execution as key drivers for the alternative asset manager's upgraded rating and bullish outlook.